Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation?
Tomkins-Netzer, O, Taylor, SRJ and Lightman, S (2013) Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmologica, 230 (3). pp. 109-115.
Full text not available from this repository.Abstract
Treatment of non-infectious uveitis is based primarily on the use of systemic corticosteroids and second-line immunosuppressive drugs. However, their extensive side effect profile, particularly for steroids, has led to the increased use of other immunosuppressive drugs, as sparing capacity agents. Rituximab is an anti-CD20 chimeric antibody, often given as a single course of 2 infusions, resulting in complete depletion of peripheral mature B cells. While it is licensed to treat refractory systemic lymphoma patients, it has also shown promising results in systemic auto-immune diseases, where a single course of treatment is able to achieve long-term clinical remission. Treatment with rituximab has been reported for various ocular conditions, suggesting it may be effective in inducing long-term disease control and other systemic immunosuppressive agents can be reduced or discontinued. When disease relapse occurs, a further course or courses can be given with good results. This review summarizes the current evidence regarding the role of rituximab in treating non-infectious uveitis. © 2013 S. Karger AG, Basel.
Item Type: | Article | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Divisions : | Surrey research (other units) | ||||||||||||
Authors : |
|
||||||||||||
Date : | 1 September 2013 | ||||||||||||
DOI : | 10.1159/000351426 | ||||||||||||
Depositing User : | Symplectic Elements | ||||||||||||
Date Deposited : | 17 May 2017 10:41 | ||||||||||||
Last Modified : | 24 Jan 2020 19:50 | ||||||||||||
URI: | http://epubs.surrey.ac.uk/id/eprint/828783 |
Actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year